The Peking University People's Hospital, Beijing, Beijng, China (Recruiting) - 31 Oct `25VC005 tablets for nonsegmental vitiligo

VC005 tablets for nonsegmental vitiligo

Official title: A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

Status: Recruiting now

Description:

Jiangsu vcare pharmaceutical technology co., LTD plans to enroll about 120 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 75 may qualify. The study is recruiting at one listed site in China.

Start date: October 31, 2025

Completion date: August 30, 2027

Organizer: Jiangsu vcare pharmaceutical technology co., LTD

Contact: xiaojuan lai

Tel.: 1 535 816 045 8

Email: lai_xiaojuan@vcarepharmatech.com

Link: https://clinicaltrials.gov/study/NCT07172347

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference VC005 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Safety of clinical trials. Can my child leave it for any reason?

    Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...

  • Does vitiligo increase the risk of skin cancer?

    No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...